These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21533174)

  • 21. Oncogenic mutations in extramammary Paget's disease and their clinical relevance.
    Kang Z; Xu F; Zhang QA; Wu Z; Zhang X; Xu J; Luo Y; Guan M
    Int J Cancer; 2013 Feb; 132(4):824-31. PubMed ID: 22821211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
    Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
    Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
    Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
    Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
    Kwiatkowski DJ
    Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
    Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
    Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biallelic TSC gene inactivation in tuberous sclerosis complex.
    Crino PB; Aronica E; Baltuch G; Nathanson KL
    Neurology; 2010 May; 74(21):1716-23. PubMed ID: 20498439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
    Ross RL; Askham JM; Knowles MA
    Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
    Miyazaki M; McCarthy JJ; Esser KA
    FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
    Groesser L; Herschberger E; Landthaler M; Hafner C
    Br J Dermatol; 2012 Apr; 166(4):784-8. PubMed ID: 22188534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.
    Pymar LS; Platt FM; Askham JM; Morrison EE; Knowles MA
    Hum Mol Genet; 2008 Jul; 17(13):2006-17. PubMed ID: 18397877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A defect in protein farnesylation suppresses a loss of Schizosaccharomyces pombe tsc2+, a homolog of the human gene predisposing to tuberous sclerosis complex.
    Nakase Y; Fukuda K; Chikashige Y; Tsutsumi C; Morita D; Kawamoto S; Ohnuki M; Hiraoka Y; Matsumoto T
    Genetics; 2006 Jun; 173(2):569-78. PubMed ID: 16624901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
    Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
    Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
    Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
    De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
    Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.
    Hafner C; Toll A; Fernández-Casado A; Earl J; Marqués M; Acquadro F; Méndez-Pertuz M; Urioste M; Malats N; Burns JE; Knowles MA; Cigudosa JC; Hartmann A; Vogt T; Landthaler M; Pujol RM; Real FX
    Proc Natl Acad Sci U S A; 2010 Nov; 107(48):20780-5. PubMed ID: 21078999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis.
    Jones AC; Shyamsundar MM; Thomas MW; Maynard J; Idziaszczyk S; Tomkins S; Sampson JR; Cheadle JP
    Am J Hum Genet; 1999 May; 64(5):1305-15. PubMed ID: 10205261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.
    Presneau N; Shalaby A; Idowu B; Gikas P; Cannon SR; Gout I; Diss T; Tirabosco R; Flanagan AM
    Br J Cancer; 2009 May; 100(9):1406-14. PubMed ID: 19401700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events.
    Qin W; Chan JA; Vinters HV; Mathern GW; Franz DN; Taillon BE; Bouffard P; Kwiatkowski DJ
    Brain Pathol; 2010 Nov; 20(6):1096-105. PubMed ID: 20633017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours.
    Knowles MA; Hornigold N; Pitt E
    Biochem Soc Trans; 2003 Jun; 31(Pt 3):597-602. PubMed ID: 12773163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.
    Dabora SL; Jozwiak S; Franz DN; Roberts PS; Nieto A; Chung J; Choy YS; Reeve MP; Thiele E; Egelhoff JC; Kasprzyk-Obara J; Domanska-Pakiela D; Kwiatkowski DJ
    Am J Hum Genet; 2001 Jan; 68(1):64-80. PubMed ID: 11112665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.